DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Simvastatin (Drug); 10 mg BI 1356 BS (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

Investigation of the multiple dose pharmacokinetics, safety and tolerability of simvastatin and simvastatin acid with and without concomitant administration of BI 1356 BS

Clinical Details

Official title: The Effect of Multiple Oral Doses of BI 1356 BS as Tablets Once Daily for Six Days on the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of 40 mg Simvastatin Given Once Daily for 20 Days and on the Pharmacokinetics of Its Metabolite Simvastatin Acid. An Open-label Study in Healthy Male Volunteers.

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

AUCτ,ss (area under the concentration-time curve of simvastatin in plasma at steady state over a uniform dosing interval τ)

Cmax,ss (maximum measured concentration of simvastatin in plasma at steady state over a uniform dosing interval τ)

Secondary outcome:

Tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)

Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)

λz,ss (terminal rate constant in plasma at steady state)

t1/2,ss (terminal half-life of the analyte in plasma at steady state)

MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)

CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)

Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)

AUCτ,ss (area under the concentration-time curve of simvastatin acid and BI 1356 BS in plasma at steady state over a uniform dosing interval τ)

Cmax,ss (maximum measured concentration of simvastatin acid and BI 1356 BS in plasma at steady state over a uniform dosing interval τ)

Number of patients with adverse events

Clinically relevant changes in clinical laboratory values

Assessment of tolerability by investigator on a 4-point scale

Eligibility

Minimum age: 21 Years. Maximum age: 65 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Healthy male subjects according to the following criteria: No findings deviating from

normal and of clinical relevance as well as no evidence of a clinically relevant concomitant disease based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests

- Age ≥21 and Age ≤65 years

- BMI ≥18. 5 and BMI ≤29. 9 kg/m2 (Body Mass Index)

- Signed and dated written informed consent prior to admission to the study in

accordance with Good Clinical Practice (GCP) and the local legislation Exclusion Criteria:

- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,

immunological or hormonal disorders

- Surgery of gastrointestinal tract (except appendectomy)

- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

or-neurological disorders

- History of relevant orthostatic hypotension, fainting spells or blackouts

- Chronic or relevant acute infections

- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant

to the trial as judged by the investigator

- Intake of drugs with a long half-life (> 24 hours) within at least one month or less

than 10 half-lives of the respective drug prior to administration or during the trial

- Use of drugs, including herbal products, which might reasonably influence the results

of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial

- Participation in another trial with an investigational drug within two months prior

to administration or during the trial

- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)

- Inability to refrain from smoking on trial days

- Alcohol abuse (more than 60 g/day)

- Drug abuse

- Blood donation (more than 100 mL within four weeks prior to administration or during

the trial)

- Excessive physical activities (within one week prior to administration or during the

trial)

- Any laboratory value outside the reference range that is of clinical relevance

- Inability to comply with dietary regimen of study centre

- Not willing to use adequate contraception (condom use plus another form of

contraception e. g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until one month after the last intake

Locations and Contacts

Additional Information

Starting date: September 2005
Last updated: July 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017